Abstract Search

ea0094p366 | Neuroendocrinology and Pituitary | SFEBES2023

MGMT and MSH2 immunohistochemistry status identifies a pituitary tumour subgroup with excellent progression free survival response to temozolomide: a single centre case series

Whitelaw Ben , Gilbert Jackie , Ling Chuah Ling , Crane James , Dimitriadis Georgios , Thomas Nick , Barazi Sinan , Maratos Eleni , Shapey Jonathan , Laniba Leah , Lazaro Nila , Gordon Nadia , Al-Salihi Omar , King Andrew , Al-Sarraj Safa , Reisz Zita , Bodi Istvan , Al Busaidi Ayisha , U-King-IM Jean-Marie , Aylwin Simon

Temozolomide has an established role as first line chemotherapy for aggressive pituitary adenoma and carcinoma. There are mixed reports whether the MGMT (methylguanine methyltransferase) and mismatch repair protein (MSH2/6) status of a tumour, assessed by immunohistochemistry (IHC) can predict response to temozolomide. This is the first series to assess combined MGMT and MSH2 status. We analysed a retrospective case series of patients treated with temozolomide at our tertiary ...

0 shares

Endocrine Abstracts

MGMT and MSH2 immunohistochemistry status identifies a pituitary tumour subgroup with excellent progression free survival response to temozolomide: a single centre case series

BiosciAbstracts